This site is intended for healthcare professionals

Aurinia announces additional analysis of its AURORA 1 phase III study data for lupus nephritis presented at ERA-EDTA 2021 congress

Read time: 1 mins
Last updated:9th Jun 2021
Published:9th Jun 2021
Aurinia Pharmaceuticals Inc. presented an analysis of its Phase III AURORA 1 study data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress .
Condition: Lupus Nephritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest